` GLS (Glenmark Life Sciences Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

G
GLS
vs
B
BSE Sensex 30

Over the past 12 months, GLS has underperformed BSE Sensex 30, delivering a return of +8% compared to the BSE Sensex 30's +10% growth.

Stocks Performance
GLS vs BSE Sensex 30

Loading
GLS
BSE Sensex 30
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
GLS vs BSE Sensex 30

Loading
GLS
BSE Sensex 30
Difference
www.alphaspread.com

Performance By Year
GLS vs BSE Sensex 30

Loading
GLS
BSE Sensex 30
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Glenmark Life Sciences Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Glenmark Life Sciences Ltd
Glance View

Market Cap
134.9B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd., a spin-off from the parent company Glenmark Pharmaceuticals, has carved out its niche in the competitive world of active pharmaceutical ingredients (APIs). This Mumbai-based entity emerged as an independent public company, growing its presence in both the domestic and international markets. Glenmark Life Sciences strategically focuses on the manufacture and supply of high-quality APIs used across a diverse range of therapeutic areas including cardiovascular, central nervous system disorders, diabetes, pain management, and oncology. By maintaining a robust portfolio of over 120 APIs, the company ensures its penetration in the growing pharmaceutical sector, which increasingly demands reliable and efficient raw materials for drug production. Through its four state-of-the-art manufacturing facilities, Glenmark Life Sciences capitalizes on its well-established research and development capabilities to enhance its manufacturing processes and expand its product range. The company's business model is meticulously designed around long-term relationships with major pharmaceutical players, fostering partnerships that drive consistent revenue streams. By leveraging cost-effective manufacturing practices and an expansive distribution network across major pharmaceutical markets, Glenmark Life Sciences not only optimizes its production capabilities but also ensures timely delivery and high-quality standards. The company's success rests on its ability to balance operational efficiency with strategic expansion into high-growth markets, reinforcing its reputation as a reliable API supplier in the global pharmaceutical industry.

GLS Intrinsic Value
Not Available
G
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett